statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases $66,605.66 in Stock

Design Therapeutics, Inc. (NASDAQ:DSGN  Get Free Report) Director John P. Schmid purchased 17,809 shares of Design Therapeutics stock in a transaction dated Monday, March 25th. The shares were...

Design Therapeutics (DSGN, $3.9) RSI Indicator left the overbought zone on March 27, 2024

This is a signal that DSGN's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Design Therapeutics (DSGN, $3.58) RSI Indicator left the overbought zone on March 26, 2024

Equities Analysts Set Expectations for Design Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:DSGN)

Design Therapeutics, Inc. (NASDAQ:DSGN  Free Report)  Analysts at Leerink Partnrs boosted their Q1 2024 EPS estimates for shares of Design Therapeutics in a research report issued on...

Design Therapeutics (DSGN, $3.25) RSI Indicator left the overbought zone on March 21, 2024

Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Hold" from Brokerages

Design Therapeutics, Inc. (NASDAQ:DSGN  Get Free Report) has been given a consensus recommendation of Hold by the seven research firms that are currently covering the company...

Design Therapeutics (NASDAQ:DSGN) Receives "Neutral" Rating from Wedbush

Design Therapeutics (NASDAQ:DSGN  Get Free Report)s stock had its neutral rating reissued by Wedbush in a report issued on Wednesday, Benzinga reports. They presently have...

Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress

Advancements in GeneTAC Platform and Strong Cash Position HighlightedRelated Stocks: DSGN...

Design Therapeutics reports Q4 EPS (21c), consensus (31c)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Design Therapeutics Outlines Progress Across GeneTAC  Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in...

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

Volume	229,885.00
52-Wk High	$8.31
52-Wk Low	$1.94

DSGN Design Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals